ipos0_l

Regeneron’s Eylea wins FDA approval for wet age-related macular degeneration

pharmafile | August 20, 2018 | News story | Sales and Marketing |  Bayer, Eylea, FDA, Regeneron, US, pharma 

Regeneron is celebrating the approval in the US of its vascular endothelial growth factor (VEGF) inhibitor Eylea (aflibercept) for the treatment of wet age-related macular degeneration (AMD).

The decision was based on second-year Phase 3 data from two trials, demonstrating the efficacy of Eylea in treating wet AMD with a 12-week dosing schedule.

Earlier the same week, the US regulator had voiced its dissatisfaction in the level of data supplied in support of the drug in a complete response letter, but had changed its mind by the Friday, with no reason given for the U-turn.

“We are pleased that the FDA has approved an updated label for EYLEA,” said Dr George D Yancopoulos, President and Chief Scientific Officer of Regeneron. “Providing information to retinal physicians about the visual outcomes with a modified 12-week dosing schedule will help physicians make the most informed choices in treating patients suffering from wet age-related macular degeneration.”

Advertisement

Last month, Eylea also secured approval in Europe, under Regeneron’s partner Bayer, who is handling commercialisation in the region. Overall, the drug is now approved for the treatment of wet AMD on four- and eight-week dosing intervals after three initial monthly doses.

Matt Fellows

Related Content

Amphista doses first patient in AML trial of protein degrader

Amphista Therapeutics has dosed the first patient in a phase 1 trial of AMX-883, an …

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

The Gateway to Local Adoption Series

Latest content